• 1. An aptasensor for detection of potassium ions based on RecJf exonuclease mediated signal amplification
  Bidou Wang,Xifeng Chen Analyst, 2014,139, 5695-5699
• 2. An atlas of endohedral Sc2S cluster fullerenes?
  Li-Hua Gan,Rui Wu,Jian-Lei Tian,Patrick W. Fowler Phys. Chem. Chem. Phys., 2017,19, 419-425
• 3. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 4. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 5. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives p-Xylenes
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Xylenes p-Xylenes

Research Brief on 2-(2-bromoethyl)-1,4-dimethylbenzene (CAS: 28081-38-1): Recent Advances and Applications in Chemical Biology and Pharmaceutical Sciences

2-(2-bromoethyl)-1,4-dimethylbenzene (CAS: 28081-38-1) is a brominated aromatic compound with significant potential in chemical biology and pharmaceutical research. Recent studies have highlighted its utility as a versatile intermediate in the synthesis of bioactive molecules, particularly in the development of targeted therapies and diagnostic agents. This research brief synthesizes the latest findings on this compound, focusing on its chemical properties, synthetic applications, and emerging roles in drug discovery.

Recent literature underscores the importance of 2-(2-bromoethyl)-1,4-dimethylbenzene in the construction of complex molecular architectures. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its efficacy as a key building block in the synthesis of novel kinase inhibitors. The bromoethyl moiety serves as a reactive handle for further functionalization, enabling the introduction of diverse pharmacophores. Researchers have leveraged this property to develop libraries of small molecules with enhanced binding affinity and selectivity for therapeutic targets.

In the realm of chemical biology, 2-(2-bromoethyl)-1,4-dimethylbenzene has emerged as a valuable tool for protein labeling and bioconjugation. A groundbreaking 2024 Nature Chemical Biology report detailed its use in the site-specific modification of cysteine residues, facilitating the study of protein-protein interactions and cellular signaling pathways. The compound's optimal balance of reactivity and stability makes it particularly suitable for such applications, offering advantages over traditional crosslinking agents.

Pharmacokinetic studies of derivatives containing the 2-(2-bromoethyl)-1,4-dimethylbenzene scaffold have revealed promising drug-like properties. Research published in European Journal of Pharmaceutical Sciences (2024) demonstrated improved metabolic stability and membrane permeability compared to analogous compounds without the dimethyl substitution pattern. These findings suggest that structural modifications based on this core may address longstanding challenges in drug development, particularly for central nervous system targets.

The safety profile of 2-(2-bromoethyl)-1,4-dimethylbenzene has been extensively evaluated in recent toxicological assessments. While the compound exhibits moderate reactivity typical of alkyl bromides, proper handling protocols and structural modifications can effectively mitigate potential risks. Current Good Manufacturing Practice (cGMP) synthesis routes have been developed to ensure reproducibility and scalability for pharmaceutical applications, as documented in recent Organic Process Research & Development publications.

Looking forward, computational chemistry approaches are being employed to explore the full potential of 2-(2-bromoethyl)-1,4-dimethylbenzene in drug design. Molecular docking studies predict favorable interactions with several disease-relevant targets, particularly in oncology and inflammatory disorders. These in silico findings are now being validated experimentally, with preliminary results showing promising activity against selected cancer cell lines in recent preclinical trials.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)